{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T12:01:17Z","timestamp":1793275277906,"version":"4.5.0"},"reference-count":251,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100000145","name":"Alberta Innovates - Health Solutions","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000145","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["PJT-153317"],"award-info":[{"award-number":["PJT-153317"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["PJT-148656"],"award-info":[{"award-number":["PJT-148656"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["PJT-165967"],"award-info":[{"award-number":["PJT-165967"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology &amp; Therapeutics"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.pharmthera.2022.108275","type":"journal-article","created":{"date-parts":[[2022,8,28]],"date-time":"2022-08-28T01:19:57Z","timestamp":1661649597000},"page":"108275","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":50,"special_numbering":"C","title":["Targeting mGluR2\/3 for treatment of neurodegenerative and neuropsychiatric diseases"],"prefix":"10.1016","volume":"239","author":[{"given":"Si Han","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khaled S.","family":"Abd-Elrahman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen S.G.","family":"Ferguson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"662","key":"10.1016\/j.pharmthera.2022.108275_bb0005","doi-asserted-by":"crossref","first-page":"eabd2494","DOI":"10.1126\/scisignal.abd2494","article-title":"A\u03b2 oligomers induce pathophysiological mGluR5 signaling in Alzheimer\u2019s disease model mice in a sex-selective manner","volume":"13","author":"Abd-Elrahman","year":"2020","journal-title":"Science Signaling"},{"key":"10.1016\/j.pharmthera.2022.108275_bb0010","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1146\/annurev-pharmtox-021821-091747","article-title":"Noncanonical metabotropic glutamate receptor 5 signaling in Alzheimer\u2019s disease","volume":"62","author":"Abd-Elrahman","year":"2022","journal-title":"Annual Review of Pharmacology and Toxicology"},{"issue":"2","key":"10.1016\/j.pharmthera.2022.108275_bb0015","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1021\/acsptsci.0c00013","article-title":"mGluR5 contribution to neuropathology in Alzheimer mice is disease stage-dependent","volume":"3","author":"Abd-Elrahman","year":"2020","journal-title":"ACS Pharmacology & Translational Science"},{"issue":"510","key":"10.1016\/j.pharmthera.2022.108275_bb0020","doi-asserted-by":"crossref","first-page":"eaan6387","DOI":"10.1126\/scisignal.aan6387","article-title":"mGluR5 antagonism increases autophagy and prevents disease progression in the zQ175 mouse model of Huntington\u2019s disease","volume":"10","author":"Abd-Elrahman","year":"2017","journal-title":"Science Signaling"},{"key":"10.1016\/j.pharmthera.2022.108275_bb0025","article-title":"The role of neuroglial metabotropic glutamate receptors in Alzheimer\u2019s disease","author":"Abd-Elrahman","year":"2021","journal-title":"Current Neuropharmacology"},{"issue":"4","key":"10.1016\/j.pharmthera.2022.108275_bb0030","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1152\/jn.1996.76.4.2691","article-title":"Metabotropic glutamate receptors coupled to IP3 production mediate inhibition of IAHP in rat dentate granule neurons","volume":"76","author":"Abdul-Ghani","year":"1996","journal-title":"Journal of Neurophysiology"},{"issue":"1","key":"10.1016\/j.pharmthera.2022.108275_bb0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-244X-13-143","article-title":"A long-term, phase 2, multicenter, randomized, open-label, comparative safety study of pomaglumetad methionil (LY2140023 monohydrate) versus atypical antipsychotic standard of care in patients with schizophrenia","volume":"13","author":"Adams","year":"2013","journal-title":"BMC Psychiatry"},{"issue":"2","key":"10.1016\/j.pharmthera.2022.108275_bb0040","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1124\/jpet.106.105387","article-title":"Pharmacological stimulation of group ii metabotropic glutamate receptors reduces cocaine self-administration and cocaine-induced reinstatement of drug seeking in squirrel monkeys","volume":"318","author":"Adewale","year":"2006","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"issue":"1","key":"10.1016\/j.pharmthera.2022.108275_bb0045","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/srep28649","article-title":"The AMPA receptor antagonist perampanel robustly rescues amyotrophic lateral sclerosis (ALS) pathology in sporadic ALS model mice","volume":"6","author":"Akamatsu","year":"2016","journal-title":"Scientific Reports"},{"issue":"1","key":"10.1016\/j.pharmthera.2022.108275_bb0050","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1523\/JNEUROSCI.16-01-00019.1996","article-title":"Selective alterations in gene expression for NMDA receptor subunits in prefrontal cortex of schizophrenics","volume":"16","author":"Akbarian","year":"1996","journal-title":"Journal of Neuroscience"},{"issue":"2","key":"10.1016\/j.pharmthera.2022.108275_bb0055","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/S0306-4522(01)00181-6","article-title":"Immunohistochemical localization of group I and II metabotropic glutamate receptors in control and amyotrophic lateral sclerosis human spinal cord: Upregulation in reactive astrocytes","volume":"105","author":"Aronica","year":"2001","journal-title":"Neuroscience"},{"issue":"10","key":"10.1016\/j.pharmthera.2022.108275_bb0060","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1046\/j.1460-9568.2003.02657.x","article-title":"Expression and functional role of mGluR3 and mGluR5 in human astrocytes and glioma cells: Opposite regulation of glutamate transporter proteins","volume":"17","author":"Aronica","year":"2003","journal-title":"European Journal of Neuroscience"},{"issue":"12","key":"10.1016\/j.pharmthera.2022.108275_bb0065","doi-asserted-by":"crossref","first-page":"2932","DOI":"10.1038\/npp.2016.107","article-title":"The mGluR2 positive allosteric modulator, AZD8529, and cue-induced relapse to alcohol seeking in rats","volume":"41","author":"Augier","year":"2016","journal-title":"Neuropsychopharmacology"},{"issue":"1\u20133","key":"10.1016\/j.pharmthera.2022.108275_bb0070","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.ejphar.2005.10.051","article-title":"Suppression of alcohol self-administration and cue-induced reinstatement of alcohol seeking by the mGlu2\/3 receptor agonist LY379268 and the mGlu8 receptor agonist (S)-3, 4-DCPG","volume":"528","author":"B\u00e4ckstr\u00f6m","year":"2005","journal-title":"European Journal of Pharmacology"},{"issue":"20","key":"10.1016\/j.pharmthera.2022.108275_bb0075","doi-asserted-by":"crossref","first-page":"4723","DOI":"10.1523\/JNEUROSCI.0176-04.2004","article-title":"Preferential effects of the metabotropic glutamate 2\/3 receptor agonist LY379268 on conditioned reinstatement versus primary reinforcement: Comparison between cocaine and a potent conventional reinforcer","volume":"24","author":"Baptista","year":"2004","journal-title":"Journal of Neuroscience"},{"issue":"12","key":"10.1016\/j.pharmthera.2022.108275_bb0080","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1016\/j.bmcl.2004.04.017","article-title":"SAR study of a subtype selective allosteric potentiator of metabotropic glutamate 2 receptor, N-(4-phenoxyphenyl)-N-(3-pyridinylmethyl)ethanesulfonamide","volume":"14","author":"Barda","year":"2004","journal-title":"Bioorganic & Medicinal Chemistry Letters"},{"issue":"8","key":"10.1016\/j.pharmthera.2022.108275_bb0085","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0006591","article-title":"Activation of mGlu3 receptors stimulates the production of GDNF in striatal neurons","volume":"4","author":"Battaglia","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2022.108275_bb0090","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.nbd.2014.11.012","article-title":"Activation of mGlu3 metabotropic glutamate receptors enhances GDNF and GLT-1 formation in the spinal cord and rescues motor neurons in the SOD-1 mouse model of amyotrophic lateral sclerosis","volume":"74","author":"Battaglia","year":"2015","journal-title":"Neurobiology of Disease"},{"issue":"15","key":"10.1016\/j.pharmthera.2022.108275_bb0095","doi-asserted-by":"crossref","first-page":"3338","DOI":"10.1096\/fasebj.6.15.1464368","article-title":"Mechanisms of excitotoxicity in neurologic diseases","volume":"6","author":"Beal","year":"1992","journal-title":"The FASEB Journal"},{"issue":"10","key":"10.1016\/j.pharmthera.2022.108275_bb0100","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1016\/S0028-3908(99)00098-2","article-title":"Selective activation of group II mGluRs with LY354740 does not prevent neuronal excitotoxicity","volume":"38","author":"Behrens","year":"1999","journal-title":"Neuropharmacology"},{"issue":"1","key":"10.1016\/j.pharmthera.2022.108275_bb0105","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1056\/NEJMra073096","article-title":"Major depressive disorder","volume":"358","author":"Belmaker","year":"2008","journal-title":"New England Journal of Medicine"},{"issue":"8","key":"10.1016\/j.pharmthera.2022.108275_bb0110","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1038\/mt.2010.107","article-title":"Macrophage-mediated GDNF delivery protects against dopaminergic neurodegeneration: A therapeutic strategy for Parkinson\u2019s disease","volume":"18","author":"Biju","year":"2010","journal-title":"Molecular Therapy"},{"issue":"9","key":"10.1016\/j.pharmthera.2022.108275_bb0115","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1021\/acsmedchemlett.7b00279","article-title":"Design and synthesis of mGlu2 NAMs with improved potency and CNS penetration based on a truncated picolinamide core","volume":"8","author":"Bollinger","year":"2017","journal-title":"ACS Medicinal Chemistry Letters"},{"key":"10.1016\/j.pharmthera.2022.108275_bb0120","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.neuropharm.2017.06.020","article-title":"In-vivo effects of knocking-down metabotropic glutamate receptor 5 in the SOD1G93A mouse model of amyotrophic lateral sclerosis","volume":"123","author":"Bonifacino","year":"2017","journal-title":"Neuropharmacology"},{"issue":"9","key":"10.1016\/j.pharmthera.2022.108275_bb0125","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1097\/00001756-200506210-00026","article-title":"The novel mGluR2\/3 agonist LY379268 attenuates cue-induced reinstatement of heroin seeking","volume":"16","author":"Bossert","year":"2005","journal-title":"Neuroreport"},{"issue":"8","key":"10.1016\/j.pharmthera.2022.108275_bb0130","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/S0028-3908(98)00091-4","article-title":"Comparative effect of l-CCG-I, DCG-IV and \u03b3-carboxy-l-glutamate on all cloned metabotropic glutamate receptor subtypes","volume":"37","author":"Brabet","year":"1998","journal-title":"Neuropharmacology"},{"issue":"14","key":"10.1016\/j.pharmthera.2022.108275_bb0135","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1021\/jm000007r","article-title":"Ligands for glutamate receptors: Design and therapeutic prospects","volume":"43","author":"Br\u00e4uner-Osborne","year":"2000","journal-title":"Journal of Medicinal Chemistry"},{"issue":"23","key":"10.1016\/j.pharmthera.2022.108275_bb0140","doi-asserted-by":"crossref","first-page":"9594","DOI":"10.1523\/JNEUROSCI.18-23-09594.1998","article-title":"Neuroprotection by glial metabotropic glutamate receptors is mediated by transforming growth factor-\u03b2","volume":"18","author":"Bruno","year":"1998","journal-title":"Journal of Neuroscience"},{"key":"10.1016\/j.pharmthera.2022.108275_bb0145","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.893422","article-title":"Targeting the type 5 metabotropic glutamate receptor: A potential therapeutic strategy for neurodegenerative diseases?","volume":"13","author":"Budgett","year":"2022","journal-title":"Frontiers in Pharmacology"},{"issue":"10","key":"10.1016\/j.pharmthera.2022.108275_bb0150","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1056\/NEJMra023160","article-title":"Drug addiction","volume":"349","author":"Cami","year":"2003","journal-title":"New England Journal of Medicine"},{"issue":"4","key":"10.1016\/j.pharmthera.2022.108275_bb0155","doi-asserted-by":"crossref","first-page":"152","DOI":"10.3109\/01677063.2011.627485","article-title":"Characterization of an mGluR2\/3 negative allosteric modulator in rodent models of depression","volume":"25","author":"Campo","year":"2011","journal-title":"Journal of Neurogenetics"},{"issue":"10","key":"10.1016\/j.pharmthera.2022.108275_bb0160","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1038\/npp.2013.106","article-title":"The mGluR2\/3 agonist LY379268 induced anti-reinstatement effects in rats exhibiting addiction-like behavior","volume":"38","author":"Cannella","year":"2013","journal-title":"Neuropsychopharmacology"},{"issue":"7","key":"10.1016\/j.pharmthera.2022.108275_bb0165","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.biopsych.2015.02.018","article-title":"Effect of the novel positive allosteric modulator of metabotropic glutamate receptor 2 AZD8529 on incubation of methamphetamine craving after prolonged voluntary abstinence in a rat model","volume":"78","author":"Caprioli","year":"2015","journal-title":"Biological Psychiatry"},{"issue":"3","key":"10.1016\/j.pharmthera.2022.108275_bb0170","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1124\/mol.110.067488","volume":"79","author":"Caraci","year":"2011","journal-title":"Molecular Pharmacology"},{"issue":"8","key":"10.1016\/j.pharmthera.2022.108275_bb0175","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/j.neuropharm.2004.08.018","article-title":"The mGlu2\/3 receptor agonist LY379268 injected into cortex or thalamus decreases neuronal injury in retrosplenial cortex produced by NMDA receptor antagonist MK-801: Possible implications for psychosis","volume":"47","author":"Carter","year":"2004","journal-title":"Neuropharmacology"},{"issue":"1","key":"10.1016\/j.pharmthera.2022.108275_bb0180","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0022-3565(24)35084-0","article-title":"The metabotropic glutamate 2\/3 receptor agonists LY354740 and LY379268 selectively attenuate phencyclidine versus d-amphetamine motor behaviors in rats","volume":"291","author":"Cartmell","year":"1999","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"issue":"4","key":"10.1016\/j.pharmthera.2022.108275_bb0185","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s002130050072","article-title":"Attenuation of specific PCP-evoked behaviors by the potent mGlu2\/3 receptor agonist, LY379268 and comparison with the atypical antipsychotic, clozapine","volume":"148","author":"Cartmell","year":"2000","journal-title":"Psychopharmacology"},{"issue":"1","key":"10.1016\/j.pharmthera.2022.108275_bb0190","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1517\/13543776.2014.983899","article-title":"Novel metabotropic glutamate receptor 2\/3 antagonists and their therapeutic applications: A patent review (2005\u2013present)","volume":"25","author":"Celanire","year":"2015","journal-title":"Expert Opinion on Therapeutic Patents"},{"issue":"4","key":"10.1016\/j.pharmthera.2022.108275_bb0195","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.neuropharm.2003.10.009","article-title":"MGS0039: A potent and selective group II metabotropic glutamate receptor antagonist with antidepressant-like activity","volume":"46","author":"Chaki","year":"2004","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pharmthera.2022.108275_bb0200","article-title":"Neuroprotection and functional recovery associated with decreased microglial activation following selective activation of mGluR2\/3 receptors in a rodent model of Parkinson\u2019s disease","volume":"2010","author":"Chan","year":"2010","journal-title":"Parkinson\u2019s Disease"},{"issue":"24","key":"10.1016\/j.pharmthera.2022.108275_bb0205","doi-asserted-by":"crossref","first-page":"10974","DOI":"10.1021\/acs.jmedchem.6b01119","volume":"59","author":"Chappell","year":"2016","journal-title":"Journal of Medicinal Chemistry"},{"issue":"5","key":"10.1016\/j.pharmthera.2022.108275_bb0210","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1046\/j.1471-4159.1999.0721890.x","article-title":"Subtype-specific enhancement of NMDA receptor currents by mutant huntingtin","volume":"72","author":"Chen","year":"1999","journal-title":"Journal of Neurochemistry"},{"issue":"16","key":"10.1016\/j.pharmthera.2022.108275_bb0215","doi-asserted-by":"crossref","first-page":"3935","DOI":"10.1113\/jphysiol.2013.255075","article-title":"SNARE proteins are essential in the potentiation of NMDA receptors by group II metabotropic glutamate receptors","volume":"591","author":"Cheng","year":"2013","journal-title":"The Journal of Physiology"},{"issue":"8","key":"10.1016\/j.pharmthera.2022.108275_bb0220","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/0896-6273(88)90162-6","article-title":"Glutamate neurotoxicity and diseases of the nervous system","volume":"1","author":"Choi","year":"1988","journal-title":"Neuron"},{"issue":"15","key":"10.1016\/j.pharmthera.2022.108275_bb0225","doi-asserted-by":"crossref","first-page":"6495","DOI":"10.1021\/jm500496m","article-title":"Discovery of 1-Butyl-3-chloro-4-(4-phenyl-1-piperidinyl)-(1H)-pyridone (JNJ-40411813): A Novel Positive Allosteric Modulator Of The Metabotropic Glutamate 2 Receptor","volume":"57","author":"Cid","year":"2014","journal-title":"Journal of Medicinal Chemistry"},{"issue":"1","key":"10.1016\/j.pharmthera.2022.108275_bb0230","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1146\/annurev.pharmtox.37.1.205","article-title":"Pharmacology and functions of metabotropic glutamate receptors","volume":"37","author":"Conn","year":"1997","journal-title":"Annual Review of Pharmacology and Toxicology"},{"issue":"31","key":"10.1016\/j.pharmthera.2022.108275_bb0235","doi-asserted-by":"crossref","first-page":"8297","DOI":"10.1523\/JNEUROSCI.1889-07.2007","article-title":"The use of knock-out mice unravels distinct roles for mGlu2 and mGlu3 metabotropic glutamate receptors in mechanisms of neurodegeneration\/neuroprotection","volume":"27","author":"Corti","year":"2007","journal-title":"Journal of Neuroscience"},{"issue":"4","key":"10.1016\/j.pharmthera.2022.108275_bb0240","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1176\/ajp.149.4.443","article-title":"Depression and Parkinson\u2019s disease: A review","volume":"149","author":"Cummings","year":"1992","journal-title":"The American Journal of Psychiatry"},{"issue":"4","key":"10.1016\/j.pharmthera.2022.108275_bb0245","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1021\/jm00399a030","article-title":"Synthesis, resolution, and absolute configuration of the isomers of the neuronal excitant 1-amino-1, 3-cyclopentanedicarboxylic acid","volume":"31","author":"Curry","year":"1988","journal-title":"Journal of Medicinal Chemistry"},{"issue":"6","key":"10.1016\/j.pharmthera.2022.108275_bb0250","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/S0896-6273(03)00568-3","article-title":"Parkinson\u2019s disease: Mechanisms and models","volume":"39","author":"Dauer","year":"2003","journal-title":"Neuron"},{"issue":"1\u20132","key":"10.1016\/j.pharmthera.2022.108275_bb0255","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/0304-3940(90)90555-N","article-title":"Selective activation of phosphoinositide hydrolysis by a rigid analogue of glutamate","volume":"109","author":"Desai","year":"1990","journal-title":"Neuroscience Letters"},{"issue":"1","key":"10.1016\/j.pharmthera.2022.108275_bb0260","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13024-019-0333-5","article-title":"The neuropathological diagnosis of Alzheimer\u2019s disease","volume":"14","author":"DeTure","year":"2019","journal-title":"Molecular Neurodegeneration"},{"issue":"1","key":"10.1016\/j.pharmthera.2022.108275_bb0265","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.pharmthera.2005.01.008","article-title":"Regulation of metabotropic glutamate receptor signaling, desensitization and endocytosis","volume":"111","author":"Dhami","year":"2006","journal-title":"Pharmacology & Therapeutics"},{"issue":"1","key":"10.1016\/j.pharmthera.2022.108275_bb0270","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1021\/jm1012165","article-title":"Design and synthesis of an orally active metabotropic glutamate receptor subtype-2 (mGluR2) positive allosteric modulator (PAM) that decreases cocaine self-administration in rats","volume":"54","author":"Dhanya","year":"2011","journal-title":"Journal of Medicinal Chemistry"},{"issue":"5334","key":"10.1016\/j.pharmthera.2022.108275_bb0275","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1126\/science.277.5334.1990","article-title":"Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain","volume":"277","author":"DiFiglia","year":"1997","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.pharmthera.2022.108275_bb0280","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0031-6997(24)01394-2","article-title":"The glutamate receptor ion channels","volume":"51","author":"Dingledine","year":"1999","journal-title":"Pharmacological Reviews"},{"issue":"3","key":"10.1016\/j.pharmthera.2022.108275_bb0285","first-page":"228","article-title":"Rapid and sustained antidepressant action of the mGlu2\/3 receptor antagonist MGS0039 in the social defeat stress model: Comparison with ketamine","volume":"20","author":"Dong","year":"2017","journal-title":"International Journal of Neuropsychopharmacology"},{"issue":"4","key":"10.1016\/j.pharmthera.2022.108275_bb0290","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/aps.2009.24","article-title":"Molecular mechanisms of excitotoxicity and their relevance to pathogenesis of neurodegenerative diseases","volume":"30","author":"Dong","year":"2009","journal-title":"Acta Pharmacologica Sinica"},{"issue":"15","key":"10.1016\/j.pharmthera.2022.108275_bb0295","doi-asserted-by":"crossref","first-page":"6704","DOI":"10.1021\/acs.jmedchem.7b00669","article-title":"Discovery and kinetic profiling of 7-Aryl-1, 2, 4-triazolo [4, 3-a] pyridines: Positive allosteric modulators of the metabotropic glutamate receptor 2","volume":"60","author":"Doornbos","year":"2017","journal-title":"Journal of Medicinal Chemistry"},{"issue":"1","key":"10.1016\/j.pharmthera.2022.108275_bb0300","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12888-014-0351-3","article-title":"A double-blind, placebo-controlled comparator study of LY2140023 monohydrate in patients with schizophrenia","volume":"14","author":"Downing","year":"2014","journal-title":"BMC Psychiatry"},{"issue":"7","key":"10.1016\/j.pharmthera.2022.108275_bb0305","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1038\/sj.npp.1301531","article-title":"Efficacy and tolerability of an mGlu2\/3 agonist in the treatment of generalized anxiety disorder","volume":"33","author":"Dunayevich","year":"2008","journal-title":"Neuropsychopharmacology"},{"issue":"4","key":"10.1016\/j.pharmthera.2022.108275_bb0310","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1017\/S1461145711001702","article-title":"mTOR activation is required for the antidepressant effects of mGluR2\/3 blockade","volume":"15","author":"Dwyer","year":"2012","journal-title":"International Journal of Neuropsychopharmacology"},{"issue":"5","key":"10.1016\/j.pharmthera.2022.108275_bb0315","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/0028-3908(96)84622-3","article-title":"Molecular cloning, functional expression, pharmacological characterization and chromosomal localization of the human metabotropic glutamate receptor type 3","volume":"35","author":"Emile","year":"1996","journal-title":"Neuropharmacology"},{"issue":"8","key":"10.1016\/j.pharmthera.2022.108275_bb0320","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1007\/s00213-016-4230-0","article-title":"mGluR2\/3 agonist LY379268 rescues NMDA and GABAA receptor level deficits induced in a two-hit mouse model of schizophrenia","volume":"233","author":"Engel","year":"2016","journal-title":"Psychopharmacology"},{"issue":"9","key":"10.1016\/j.pharmthera.2022.108275_bb0325","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1021\/acsmedchemlett.7b00249","article-title":"Design and synthesis of N-aryl phenoxyethoxy pyridinones as highly selective and CNS penetrant mGlu3 NAMs","volume":"8","author":"Engers","year":"2017","journal-title":"ACS Medicinal Chemistry Letters"},{"issue":"18","key":"10.1016\/j.pharmthera.2022.108275_bb0330","doi-asserted-by":"crossref","first-page":"7485","DOI":"10.1021\/acs.jmedchem.5b01005","article-title":"Discovery of a selective and CNS penetrant negative allosteric modulator of metabotropic glutamate receptor subtype 3 with antidepressant and anxiolytic activity in rodents","volume":"58","author":"Engers","year":"2015","journal-title":"Journal of Medicinal Chemistry"},{"issue":"7","key":"10.1016\/j.pharmthera.2022.108275_bb0335","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/S0960-894X(98)00091-2","article-title":"(2S,4S)-2-Amino-4-(2,2-diphenylethyl)pentanedioic acid selective group 2 metabotropic glutamate receptor antagonist","volume":"8","author":"Escribano","year":"1998","journal-title":"Bioorganic & Medicinal Chemistry Letters"},{"issue":"15","key":"10.1016\/j.pharmthera.2022.108275_bb0340","doi-asserted-by":"crossref","first-page":"3053","DOI":"10.1093\/hmg\/ddq212","article-title":"In vivo expression of polyglutamine-expanded huntingtin by mouse striatal astrocytes impairs glutamate transport: A correlation with Huntington\u2019s disease subjects","volume":"19","author":"Faideau","year":"2010","journal-title":"Human Molecular Genetics"},{"issue":"9","key":"10.1016\/j.pharmthera.2022.108275_bb0345","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1111\/bph.13065","article-title":"Molecular determinants of positive allosteric modulation of the human metabotropic glutamate receptor 2","volume":"172","author":"Farinha","year":"2015","journal-title":"British Journal of Pharmacology"},{"issue":"3","key":"10.1016\/j.pharmthera.2022.108275_bb0350","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1007\/s12035-019-01818-z","article-title":"mGluR5 allosteric modulation promotes neurorecovery in a 6-OHDA-toxicant model of Parkinson\u2019s disease","volume":"57","author":"Farmer","year":"2020","journal-title":"Molecular Neurobiology"},{"issue":"1","key":"10.1016\/j.pharmthera.2022.108275_bb0355","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1124\/jpet.108.136861","article-title":"Evidence for the Role of metabotropic glutamate (mGlu) 2 not mGlu3 receptors in the preclinical antipsychotic pharmacology of the mGlu2\/3 receptor agonist (\u2013)-(1R, 4S, 5S, 6S)-4-amino-2-sulfonylbicyclo [3.1. 0] hexane-4, 6-dicarboxylic acid (LY404039)","volume":"326","author":"Fell","year":"2008","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"issue":"1","key":"10.1016\/j.pharmthera.2022.108275_bb0360","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1124\/jpet.110.172957","volume":"336","author":"Fell","year":"2011","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"issue":"22","key":"10.1016\/j.pharmthera.2022.108275_bb0365","doi-asserted-by":"crossref","first-page":"9027","DOI":"10.1021\/acs.jmedchem.5b01371","article-title":"Design of 4-oxo-1-aryl-1, 4-dihydroquinoline-3-carboxamides as selective negative allosteric modulators of metabotropic glutamate receptor subtype 2","volume":"58","author":"Felts","year":"2015","journal-title":"Journal of Medicinal Chemistry"},{"issue":"4","key":"10.1016\/j.pharmthera.2022.108275_bb0370","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.tips.2007.02.008","article-title":"Phosphorylation-independent attenuation of GPCR signalling","volume":"28","author":"Ferguson","year":"2007","journal-title":"Trends in Pharmacological Sciences"},{"issue":"1","key":"10.1016\/j.pharmthera.2022.108275_bb0375","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1471-4159.1984.tb09689.x","article-title":"Glutamate: A neurotransmitter in mammalian brain","volume":"42","author":"Fonnum","year":"1984","journal-title":"Journal of Neurochemistry"},{"key":"10.1016\/j.pharmthera.2022.108275_bb0380","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2019.107725","article-title":"Activation of mGlu2\/3 receptors, a novel therapeutic approach to alleviate dyskinesia and psychosis in experimental parkinsonism","volume":"158","author":"Frouni","year":"2019","journal-title":"Neuropharmacology"},{"issue":"1","key":"10.1016\/j.pharmthera.2022.108275_bb0385","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1756-6606-7-31","article-title":"Comprehensive behavioral study of mGluR3 knockout mice: Implication in schizophrenia related endophenotypes","volume":"7","author":"Fujioka","year":"2014","journal-title":"Molecular Brain"},{"issue":"3","key":"10.1016\/j.pharmthera.2022.108275_bb0390","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1124\/jpet.105.091074","article-title":"A selective allosteric potentiator of metabotropic glutamate (mGlu) 2 receptors has effects similar to an orthosteric mGlu2\/3 receptor agonist in mouse models predictive of antipsychotic activity","volume":"315","author":"Galici","year":"2005","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"issue":"1","key":"10.1016\/j.pharmthera.2022.108275_bb0395","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1124\/jpet.106.102046","article-title":"Biphenyl-indanone A, a positive allosteric modulator of the metabotropic glutamate receptor subtype 2, has antipsychotic-and anxiolytic-like effects in mice","volume":"318","author":"Galici","year":"2006","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"issue":"6571","key":"10.1016\/j.pharmthera.2022.108275_bb0400","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/380252a0","article-title":"Functional recovery in parkinsonian monkeys treated with GDNF","volume":"380","author":"Gash","year":"1996","journal-title":"Nature"},{"issue":"5800","key":"10.1016\/j.pharmthera.2022.108275_bb0405","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1126\/science.1132814","article-title":"A century of Alzheimer\u2019s disease","volume":"314","author":"Goedert","year":"2006","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.pharmthera.2022.108275_bb0410","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/S0026-895X(25)09394-0","article-title":"Coupling of metabotropic glutamate receptors 2 and 4 to G alpha 15, G alpha 16, and chimeric G alpha q\/i proteins: Characterization of new antagonists","volume":"50","author":"Gomeza","year":"1996","journal-title":"Molecular Pharmacology"},{"issue":"1","key":"10.1016\/j.pharmthera.2022.108275_bb0415","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/srep35320","article-title":"The mGluR2 positive allosteric modulator, SAR218645, improves memory and attention deficits in translational models of cognitive symptoms associated with schizophrenia","volume":"6","author":"Griebel","year":"2016","journal-title":"Scientific Reports"},{"issue":"4","key":"10.1016\/j.pharmthera.2022.108275_bb0420","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1007\/s00213-003-1444-8","article-title":"Anxiolytic effects of a novel group II metabotropic glutamate receptor agonist (LY354740) in the fear-potentiated startle paradigm in humans","volume":"168","author":"Grillon","year":"2003","journal-title":"Psychopharmacology"},{"issue":"8","key":"10.1016\/j.pharmthera.2022.108275_bb0425","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1016\/j.febslet.2010.03.025","article-title":"Decreased GLT-1 and increased SOD1 and HO-1 expression in astrocytes contribute to lumbar spinal cord vulnerability of SOD1-G93A transgenic mice","volume":"584","author":"Guo","year":"2010","journal-title":"FEBS Letters"},{"issue":"7","key":"10.1016\/j.pharmthera.2022.108275_bb0430","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1038\/nm1418","article-title":"Altered neuregulin 1\u2013erbB4 signaling contributes to NMDA> receptor hypofunction in schizophrenia","volume":"12","author":"Hahn","year":"2006","journal-title":"Nature Medicine"},{"issue":"2","key":"10.1016\/j.pharmthera.2022.108275_bb0435","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.pharmthera.2004.04.001","article-title":"Rationale for and use of NMDA receptor antagonists in Parkinson\u2019s disease","volume":"102","author":"Hallett","year":"2004","journal-title":"Pharmacology & Therapeutics"},{"issue":"1","key":"10.1016\/j.pharmthera.2022.108275_bb0440","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13041-015-0107-0","article-title":"Glutamate receptors function as scaffolds for the regulation of \u03b2-amyloid and cellular prion protein signaling complexes","volume":"8","author":"Hamilton","year":"2015","journal-title":"Molecular Brain"},{"issue":"2","key":"10.1016\/j.pharmthera.2022.108275_bb0445","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1007\/s11064-007-9463-1","article-title":"Glutamate uptake is reduced in prefrontal cortex in Huntington\u2019s disease","volume":"33","author":"Hassel","year":"2008","journal-title":"Neurochemical Research"},{"issue":"2","key":"10.1016\/j.pharmthera.2022.108275_bb0450","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1111\/j.1476-5381.1992.tb12780.x","article-title":"Agonist analysis of 2-(carboxycyclopropyl) glycine isomers for cloned metabotropic glutamate receptor subtypes expressed in Chinese hamster ovary cells","volume":"107","author":"Hayashi","year":"1992","journal-title":"British Journal of Pharmacology"},{"issue":"11\u201312","key":"10.1016\/j.pharmthera.2022.108275_bb0455","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1016\/S0028-3908(97)00170-6","article-title":"LY354740: A metabotropic glutamate receptor agonist which ameliorates symptoms of nicotine withdrawal in rats","volume":"36","author":"Helton","year":"1997","journal-title":"Neuropharmacology"},{"issue":"2","key":"10.1016\/j.pharmthera.2022.108275_bb0460","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/S0022-3565(24)37253-2","article-title":"Anxiolytic and side-effect profile of LY354740: A potent, highly selective, orally active agonist for group II metabotropic glutamate receptors","volume":"284","author":"Helton","year":"1998","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"issue":"1","key":"10.1016\/j.pharmthera.2022.108275_bb0465","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1124\/jpet.106.117093","article-title":"A novel family of potent negative allosteric modulators of group II metabotropic glutamate receptors","volume":"322","author":"Hemstapat","year":"2007","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"issue":"2","key":"10.1016\/j.pharmthera.2022.108275_bb0470","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1021\/cn400023y","article-title":"Is there a path forward for mGlu2 positive allosteric modulators for the treatment of schizophrenia?","volume":"4","author":"Hopkins","year":"2013","journal-title":"ACS Chemical Neuroscience"},{"issue":"3","key":"10.1016\/j.pharmthera.2022.108275_bb0475","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1021\/acs.jmedchem.5b01333","article-title":"New 4-functionalized glutamate analogues are selective agonists at metabotropic glutamate receptor subtype 2 or selective agonists at metabotropic glutamate receptor group III","volume":"59","author":"Huynh","year":"2016","journal-title":"Journal of Medicinal Chemistry"},{"issue":"8","key":"10.1016\/j.pharmthera.2022.108275_bb0480","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/0028-3908(95)00063-C","article-title":"New phenylglycine derivatives with potent and selective antagonist activity at presynaptic glutamate receptors in neonatal rat spinal cord","volume":"34","author":"Jane","year":"1995","journal-title":"Neuropharmacology"},{"issue":"4","key":"10.1016\/j.pharmthera.2022.108275_bb0485","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1136\/jnnp.2007.131045","article-title":"Parkinson\u2019s disease: Clinical features and diagnosis","volume":"79","author":"Jankovic","year":"2008","journal-title":"Journal of Neurology, Neurosurgery & Psychiatry"},{"issue":"10","key":"10.1016\/j.pharmthera.2022.108275_bb0490","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1038\/npp.2010.82","article-title":"The mGluR2 positive allosteric modulator BINA decreases cocaine self-administration and cue-induced cocaine-seeking and counteracts cocaine-induced enhancement of brain reward function in rats","volume":"35","author":"Jin","year":"2010","journal-title":"Neuropsychopharmacology"},{"issue":"15","key":"10.1016\/j.pharmthera.2022.108275_bb0495","doi-asserted-by":"crossref","first-page":"3189","DOI":"10.1021\/jm034015u","article-title":"Discovery of Allosteric Potentiators for the Metabotropic Glutamate 2 Receptor: Synthesis and Subtype Selectivity of N-(4-(2-Methoxyphenoxy) phenyl)-N-(2, 2, 2\u2212 trifluoroethylsulfonyl) pyrid-3-ylmethylamine","volume":"46","author":"Johnson","year":"2003","journal-title":"Journal of Medicinal Chemistry"},{"issue":"1","key":"10.1016\/j.pharmthera.2022.108275_bb0500","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s00213-004-2099-9","article-title":"Metabotropic glutamate 2 receptor potentiators: Receptor modulation, frequency-dependent synaptic activity, and efficacy in preclinical anxiety and psychosis model (s)","volume":"179","author":"Johnson","year":"2005","journal-title":"Psychopharmacology"},{"issue":"1","key":"10.1016\/j.pharmthera.2022.108275_bb0505","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s00213-010-1931-7","article-title":"The mGluR2\/3 agonist LY379268 reverses post-weaning social isolation-induced recognition memory deficits in the rat","volume":"214","author":"Jones","year":"2011","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pharmthera.2022.108275_bb0510","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.neuropharm.2005.05.008","article-title":"Analgesic effects of the selective group II (mGlu2\/3) metabotropic glutamate receptor agonists LY379268 and LY389795 in persistent and inflammatory pain models after acute and repeated dosing","volume":"49","author":"Jones","year":"2005","journal-title":"Neuropharmacology"},{"issue":"9","key":"10.1016\/j.pharmthera.2022.108275_bb0515","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1021\/jm980571q","article-title":"Agonist selectivity of mGluR1 and mGluR2 metabotropic receptors: A different environment but similar recognition of an extended glutamate conformation","volume":"42","author":"Jullian","year":"1999","journal-title":"Journal of Medicinal Chemistry"},{"issue":"7","key":"10.1016\/j.pharmthera.2022.108275_bb0520","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.biopsych.2015.01.014","article-title":"The novel metabotropic glutamate receptor 2 positive allosteric modulator, AZD8529, decreases nicotine self-administration and relapse in squirrel monkeys","volume":"78","author":"Justinova","year":"2015","journal-title":"Biological Psychiatry"},{"issue":"4","key":"10.1016\/j.pharmthera.2022.108275_bb0525","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1046\/j.1471-4159.1998.70041497.x","article-title":"Repeated cocaine administration alters extracellular glutamate in the ventral tegmental area","volume":"70","author":"Kalivas","year":"1998","journal-title":"Journal of Neurochemistry"},{"key":"10.1016\/j.pharmthera.2022.108275_bb0530","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.neuropharm.2008.07.011","article-title":"Glutamate transmission in addiction","volume":"56","author":"Kalivas","year":"2009","journal-title":"Neuropharmacology"},{"issue":"1","key":"10.1016\/j.pharmthera.2022.108275_bb0535","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.brainres.2005.02.032","article-title":"AMPA receptor stimulation mediates the antidepressant-like effect of a group II metabotropic glutamate receptor antagonist","volume":"1042","author":"Karasawa","year":"2005","journal-title":"Brain Research"},{"issue":"2\u20133","key":"10.1016\/j.pharmthera.2022.108275_bb0540","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.neulet.2005.09.058","article-title":"A metabotropic glutamate 2\/3 receptor antagonist, MGS0039, increases extracellular dopamine levels in the nucleus accumbens shell","volume":"393","author":"Karasawa","year":"2006","journal-title":"Neuroscience Letters"},{"issue":"6","key":"10.1016\/j.pharmthera.2022.108275_bb0545","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1038\/mp.2012.59","article-title":"Prefrontal synaptic markers of cocaine addiction-like behavior in rats","volume":"18","author":"Kasanetz","year":"2013","journal-title":"Molecular Psychiatry"},{"issue":"3","key":"10.1016\/j.pharmthera.2022.108275_bb0550","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.neulet.2004.12.021","article-title":"Neuropharmacological profiles of antagonists of group II metabotropic glutamate receptors","volume":"378","author":"Kawashima","year":"2005","journal-title":"Neuroscience Letters"},{"issue":"1","key":"10.1016\/j.pharmthera.2022.108275_bb0555","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/0014-2999(96)00314-7","article-title":"Agonists of cyclic AMP-coupled metabotropic glutamate receptors in adult rat cortical slices","volume":"309","author":"Kemp","year":"1996","journal-title":"European Journal of Pharmacology"},{"issue":"2","key":"10.1016\/j.pharmthera.2022.108275_bb0560","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/0922-4106(94)90109-0","article-title":"Antagonism of presynaptically mediated depressant responses and cyclic AMP-coupled metabotropic glutamate receptors","volume":"266","author":"Kemp","year":"1994","journal-title":"European Journal of Pharmacology: Molecular Pharmacology"},{"key":"10.1016\/j.pharmthera.2022.108275_bb0565","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.pnpbp.2016.01.009","article-title":"Efficacy and safety of an adjunctive mGlu2 receptor positive allosteric modulator to a SSRI\/SNRI in anxious depression","volume":"67","author":"Kent","year":"2016","journal-title":"Progress in Neuro-Psychopharmacology and Biological Psychiatry"},{"issue":"1","key":"10.1016\/j.pharmthera.2022.108275_bb0570","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1460-9568.2004.03822.x","article-title":"Activation of group II mGlu receptors blocks the enhanced drug taking induced by previous exposure to amphetamine","volume":"21","author":"Kim","year":"2005","journal-title":"European Journal of Neuroscience"},{"issue":"11","key":"10.1016\/j.pharmthera.2022.108275_bb0575","doi-asserted-by":"crossref","first-page":"3870","DOI":"10.1523\/JNEUROSCI.4717-09.2010","article-title":"Group II metabotropic glutamate receptor stimulation triggers production and release of Alzheimer\u2019s amyloid \u03b242 from isolated intact nerve terminals","volume":"30","author":"Kim","year":"2010","journal-title":"Journal of Neuroscience"},{"issue":"11","key":"10.1016\/j.pharmthera.2022.108275_bb0580","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1038\/mp.2014.87","article-title":"Proneurogenic Group II mGluR antagonist improves learning and reduces anxiety in Alzheimer A\u03b2 oligomer mouse","volume":"19","author":"Kim","year":"2014","journal-title":"Molecular Psychiatry"},{"issue":"2\u20133","key":"10.1016\/j.pharmthera.2022.108275_bb0585","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0014-2999(99)00397-0","article-title":"Neuroprotection by metabotropic glutamate receptor agonists: LY354740, LY379268 and LY389795","volume":"377","author":"Kingston","year":"1999","journal-title":"European Journal of Pharmacology"},{"issue":"1","key":"10.1016\/j.pharmthera.2022.108275_bb0590","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0028-3908(97)00191-3","article-title":"LY341495 is a nanomolar potent and selective antagonist of group II metabotropic glutamate receptors","volume":"37","author":"Kingston","year":"1998","journal-title":"Neuropharmacology"},{"issue":"9","key":"10.1016\/j.pharmthera.2022.108275_bb0595","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1021\/jm00009a001","article-title":"Metabotropic glutamate receptors: Novel targets for drug development","volume":"38","author":"Kn\u00f6pfel","year":"1995","journal-title":"Journal of Medicinal Chemistry"},{"issue":"8","key":"10.1016\/j.pharmthera.2022.108275_bb0600","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/0028-3908(95)00111-I","article-title":"Pharmacological characterization of MCCG and MAP4 at the mGluR1b, mGluR2 and mGluR4a human metabotropic glutamate receptor subtypes","volume":"34","author":"Kn\u00f6pfel","year":"1995","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pharmthera.2022.108275_bb0605","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.bbr.2014.05.065","article-title":"Requirement of AMPA receptor stimulation for the sustained antidepressant activity of ketamine and LY341495 during the forced swim test in rats","volume":"271","author":"Koike","year":"2014","journal-title":"Behavioural Brain Research"},{"issue":"5492","key":"10.1016\/j.pharmthera.2022.108275_bb0610","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1126\/science.290.5492.767","article-title":"Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson\u2019s disease","volume":"290","author":"Kordower","year":"2000","journal-title":"Science"},{"issue":"12","key":"10.1016\/j.pharmthera.2022.108275_bb0615","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1016\/S0960-894X(99)00266-8","article-title":"1-Amino-APDC, a partial agonist of group II metabotropic glutamate receptors with neuroprotective properties","volume":"9","author":"Kozikowski","year":"1999","journal-title":"Bioorganic & Medicinal Chemistry Letters"},{"issue":"1","key":"10.1016\/j.pharmthera.2022.108275_bb0620","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s00213-004-1982-8","article-title":"Preliminary evidence of attenuation of the disruptive effects of the NMDA glutamate receptor antagonist, ketamine, on working memory by pretreatment with the group II metabotropic glutamate receptor agonist, LY354740, in healthy human subjects","volume":"179","author":"Krystal","year":"2005","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pharmthera.2022.108275_bb0625","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.neuropharm.2012.05.037","article-title":"Attenuation of methamphetamine seeking by the mGluR2\/3 agonist LY379268 in rats with histories of restricted and escalated self-administration","volume":"66","author":"Kufahl","year":"2013","journal-title":"Neuropharmacology"},{"issue":"2","key":"10.1016\/j.pharmthera.2022.108275_bb0630","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1038\/sj.npp.1300032","article-title":"Nicotine induces glutamate release from thalamocortical terminals in prefrontal cortex","volume":"28","author":"Lambe","year":"2003","journal-title":"Neuropsychopharmacology"},{"issue":"16","key":"10.1016\/j.pharmthera.2022.108275_bb0635","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1056\/NEJM199810153391607","article-title":"Parkinson\u2019s disease","volume":"339","author":"Lang","year":"1998","journal-title":"New England Journal of Medicine"},{"issue":"3","key":"10.1016\/j.pharmthera.2022.108275_bb0640","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1124\/jpet.113.204990","article-title":"Pharmacological characterization of JNJ-40068782, a new potent, selective, and systemically active positive allosteric modulator of the mGlu2 receptor and its radioligand [3H]JNJ-40068782","volume":"346","author":"Lavreysen","year":"2013","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"issue":"2","key":"10.1016\/j.pharmthera.2022.108275_bb0645","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.97","article-title":"Preclinical evaluation of the antipsychotic potential of the mGlu2-positive allosteric modulator JNJ-40411813","volume":"3","author":"Lavreysen","year":"2015","journal-title":"Pharmacology Research & Perspectives"},{"issue":"4","key":"10.1016\/j.pharmthera.2022.108275_bb0650","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s00401-004-0820-8","article-title":"Aberrant expression of metabotropic glutamate receptor 2 in the vulnerable neurons of Alzheimer\u2019s disease","volume":"107","author":"Lee","year":"2004","journal-title":"Acta Neuropathologica"},{"issue":"2","key":"10.1016\/j.pharmthera.2022.108275_bb0655","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.neuron.2013.09.045","article-title":"Kainate receptors in health and disease","volume":"80","author":"Lerma","year":"2013","journal-title":"Neuron"},{"key":"10.1016\/j.pharmthera.2022.108275_bb0660","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.pnpbp.2015.02.012","article-title":"Perspectives on the mGluR2\/3 agonists as a therapeutic target for schizophrenia: Still promising or a dead end?","volume":"60","author":"Li","year":"2015","journal-title":"Progress in Neuro-Psychopharmacology and Biological Psychiatry"},{"issue":"1","key":"10.1016\/j.pharmthera.2022.108275_bb0665","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1124\/jpet.121.000735","article-title":"Metabotropic glutamate receptor 2\/3 activation improves motor performance and reduces pathology in heterozygous zQ175 Huntington Disease Mice","volume":"379","author":"Li","year":"2021","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.pharmthera.2022.108275_bb0670","article-title":"Metabotropic Glutamate Receptor 5 antagonism reduces pathology and differentially improves symptoms in male and female heterozygous zQ175 Huntington\u2019s mice","volume":"15","author":"Li","year":"2022","journal-title":"Frontiers in Molecular Neuroscience"},{"issue":"34","key":"10.1016\/j.pharmthera.2022.108275_bb0675","doi-asserted-by":"crossref","first-page":"9077","DOI":"10.1523\/JNEUROSCI.1766-07.2007","article-title":"Metabotropic glutamate 2\/3 receptors in the ventral tegmental area and the nucleus accumbens shell are involved in behaviors relating to nicotine dependence","volume":"27","author":"Liechti","year":"2007","journal-title":"Journal of Neuroscience"},{"issue":"5","key":"10.1016\/j.pharmthera.2022.108275_bb0680","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1006\/nbdi.2001.0430","article-title":"Impaired glutamate uptake in the R6 Huntington\u2019s disease transgenic mice","volume":"8","author":"Lievens","year":"2001","journal-title":"Neurobiology of Disease"},{"issue":"1","key":"10.1016\/j.pharmthera.2022.108275_bb0685","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/ejn.12383","article-title":"Stimulating ERK\/PI3K\/NF\u03baB signaling pathways upon activation of mGluR2\/3 restores OGD-induced impairment in glutamate clearance in astrocytes","volume":"39","author":"Lin","year":"2014","journal-title":"European Journal of Neuroscience"},{"key":"10.1016\/j.pharmthera.2022.108275_bb0690","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.neuropharm.2016.03.036","article-title":"Metabotropic glutamate receptors as therapeutic targets in Parkinson\u2019s disease: An update from the last 5 years of research","volume":"115","author":"Litim","year":"2017","journal-title":"Neuropharmacology"},{"issue":"1\u20133","key":"10.1016\/j.pharmthera.2022.108275_bb0695","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.schres.2016.02.001","article-title":"AZD8529, a positive allosteric modulator at the mGluR2 receptor, does not improve symptoms in schizophrenia: A proof of principle study","volume":"172","author":"Litman","year":"2016","journal-title":"Schizophrenia Research"},{"issue":"3","key":"10.1016\/j.pharmthera.2022.108275_bb0700","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1001\/archneurpsyc.1959.02340150095011","article-title":"Study of a new schizophrenomimetic drug\u2014Sernyl","volume":"81","author":"Luby","year":"1959","journal-title":"AMA Archives of Neurology & Psychiatry"},{"issue":"2","key":"10.1016\/j.pharmthera.2022.108275_bb0705","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1001\/archopht.1957.00940010205006","article-title":"The toxic effect of sodium L-glutamate on the inner layers of the retina","volume":"58","author":"Lucas","year":"1957","journal-title":"AMA Archives of Ophthalmology"},{"issue":"4","key":"10.1016\/j.pharmthera.2022.108275_bb0710","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.neuron.2010.01.016","article-title":"Group 1 mGluR-dependent synaptic long-term depression: Mechanisms and implications for circuitry and disease","volume":"65","author":"L\u00fcscher","year":"2010","journal-title":"Neuron"},{"issue":"20","key":"10.1016\/j.pharmthera.2022.108275_bb0715","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1056\/NEJM198611133152006","article-title":"Huntingtons disease","volume":"315","author":"Martin","year":"1986","journal-title":"New England Journal of Medicine"},{"issue":"3","key":"10.1016\/j.pharmthera.2022.108275_bb0720","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/j.neuroscience.2007.02.053","article-title":"Group II metabotropic glutamate receptors inhibit glutamate release at thalamocortical synapses in the developing somatosensory cortex","volume":"146","author":"Mateo","year":"2007","journal-title":"Neuroscience"},{"issue":"1","key":"10.1016\/j.pharmthera.2022.108275_bb0725","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/ene.13413","article-title":"Huntington\u2019s disease: A clinical review","volume":"25","author":"McColgan","year":"2018","journal-title":"European Journal of Neurology"},{"issue":"8","key":"10.1016\/j.pharmthera.2022.108275_bb0730","doi-asserted-by":"crossref","first-page":"3531","DOI":"10.1523\/JNEUROSCI.23-08-03531.2003","article-title":"Prefrontal glutamate release into the core of the nucleus accumbens mediates cocaine-induced reinstatement of drug-seeking behavior","volume":"23","author":"McFarland","year":"2003","journal-title":"Journal of Neuroscience"},{"issue":"2","key":"10.1016\/j.pharmthera.2022.108275_bb0735","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1007\/BF00250265","article-title":"The actions of cyclopentane analogues of glutamic acid at binding sites for kainic and glutamic acids","volume":"72","author":"McLennan","year":"1988","journal-title":"Experimental Brain Research"},{"issue":"7","key":"10.1016\/j.pharmthera.2022.108275_bb0740","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.1523\/JNEUROSCI.4062-12.2013","article-title":"Rescue of infralimbic mGluR2 deficit restores control over drug-seeking behavior in alcohol dependence","volume":"33","author":"Meinhardt","year":"2013","journal-title":"Journal of Neuroscience"},{"issue":"18","key":"10.1016\/j.pharmthera.2022.108275_bb0745","doi-asserted-by":"crossref","first-page":"3747","DOI":"10.1111\/bph.15515","article-title":"Blocking glutamate mGlu5 receptors with the negative allosteric modulator CTEP improves disease course in SOD1G93A mouse model of amyotrophic lateral sclerosis","volume":"178","author":"Milanese","year":"2021","journal-title":"British Journal of Pharmacology"},{"issue":"9578","key":"10.1016\/j.pharmthera.2022.108275_bb0750","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1016\/S0140-6736(07)60944-1","article-title":"Amyotrophic lateral sclerosis","volume":"369","author":"Mitchell","year":"2007","journal-title":"The Lancet"},{"issue":"8","key":"10.1016\/j.pharmthera.2022.108275_bb0755","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.1523\/JNEUROSCI.17-08-02921.1997","article-title":"Activation of glutamatergic neurotransmission by ketamine: A novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex","volume":"17","author":"Moghaddam","year":"1997","journal-title":"Journal of Neuroscience"},{"issue":"5381","key":"10.1016\/j.pharmthera.2022.108275_bb0760","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1126\/science.281.5381.1349","article-title":"Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats","volume":"281","author":"Moghaddam","year":"1998","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.pharmthera.2022.108275_bb0765","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/S0092-8674(00)81972-8","article-title":"Mice with reduced NMDA receptor expression display behaviors related to schizophrenia","volume":"98","author":"Mohn","year":"1999","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.pharmthera.2022.108275_bb0770","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1021\/jm060917u","article-title":"Synthesis and metabotropic glutamate receptor activity of S-oxidized variants of (\u2212)-4-amino-2-thiabicyclo-[3.1. 0] hexane-4, 6-dicarboxylate: Identification of potent, selective, and orally bioavailable agonists for mGlu2\/3 receptors","volume":"50","author":"Monn","year":"2007","journal-title":"Journal of Medicinal Chemistry"},{"issue":"15","key":"10.1016\/j.pharmthera.2022.108275_bb0775","doi-asserted-by":"crossref","first-page":"2990","DOI":"10.1021\/jm9601765","article-title":"Synthesis of the four isomers of 4-aminopyrrolidine-2, 4-dicarboxylate: Identification of a potent, highly selective, and systemically-active agonist for metabotropic glutamate receptors negatively coupled to adenylate cyclase","volume":"39","author":"Monn","year":"1996","journal-title":"Journal of Medicinal Chemistry"},{"issue":"6","key":"10.1016\/j.pharmthera.2022.108275_bb0780","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1021\/jm980616n","article-title":"Synthesis, pharmacological characterization, and molecular modeling of heterobicyclic amino acids related to (+)-2-aminobicyclo [3.1. 0] hexane-2, 6-dicarboxylic acid (LY354740): Identification of two new potent, selective, and systemically active agonist","volume":"42","author":"Monn","year":"1999","journal-title":"Journal of Medicinal Chemistry"},{"issue":"11","key":"10.1016\/j.pharmthera.2022.108275_bb0785","doi-asserted-by":"crossref","first-page":"4170","DOI":"10.1073\/pnas.0500914102","article-title":"Enhanced cocaine responsiveness and impaired motor coordination in metabotropic glutamate receptor subtype 2 knockout mice","volume":"102","author":"Morishima","year":"2005","journal-title":"Proceedings of the National Academy of Sciences"},{"issue":"14","key":"10.1016\/j.pharmthera.2022.108275_bb0790","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1016\/S0960-894X(01)00329-8","article-title":"Synthesis of N1-substituted analogues of (2R, 4R)-4-amino-pyrrolidine-2, 4-dicarboxylic acid as agonists, partial agonists, and antagonists of group II metabotropic glutamate receptors","volume":"11","author":"Mukhopadhyaya","year":"2001","journal-title":"Bioorganic & Medicinal Chemistry Letters"},{"issue":"2","key":"10.1016\/j.pharmthera.2022.108275_bb0795","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/S0091-3057(02)00842-0","article-title":"Evaluation of the mGluR2\/3 agonist LY379268 in rodent models of Parkinson\u2019s disease","volume":"73","author":"Murray","year":"2002","journal-title":"Pharmacology Biochemistry and Behavior"},{"issue":"5","key":"10.1016\/j.pharmthera.2022.108275_bb0800","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/0896-6273(94)90043-4","article-title":"Metabotropic glutamate receptors: Synaptic transmission, modulation, and plasticity","volume":"13","author":"Nakanishi","year":"1994","journal-title":"Neuron"},{"issue":"18","key":"10.1016\/j.pharmthera.2022.108275_bb0805","doi-asserted-by":"crossref","first-page":"4570","DOI":"10.1021\/jm0400294","article-title":"Synthesis, in vitro pharmacology, structure\u2212 activity relationships, and pharmacokinetics of 3-alkoxy-2-amino-6-fluorobicyclo [3.1. 0] hexane-2, 6-dicarboxylic acid derivatives as potent and selective group II metabotropic glutamate receptor antagonists","volume":"47","author":"Nakazato","year":"2004","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2022.108275_bb0810","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1146\/annurev.pharmtox.011008.145533","article-title":"Metabotropic glutamate receptors: Physiology, pharmacology, and disease","volume":"50","author":"Niswender","year":"2010","journal-title":"Annual Review of Pharmacology and Toxicology"},{"key":"10.1016\/j.pharmthera.2022.108275_bb0815","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1007\/s43440-022-00378-9","article-title":"Evaluation of the effects of the mGlu2\/3 antagonist LY341495 on dyskinesia and psychosis-like behaviours in the MPTP-lesioned marmoset","volume":"74","author":"Nuara","year":"2022","journal-title":"Pharmacological Reports"},{"issue":"1","key":"10.1016\/j.pharmthera.2022.108275_bb0820","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S0960-894X(00)80083-9","article-title":"Synthesis of L-2-(2, 3-dicarboxyclopropyl) glycines. Novel conformationally restricted glutamate analogues","volume":"3","author":"Ohfune","year":"1993","journal-title":"Bioorganic & Medicinal Chemistry Letters"},{"issue":"4","key":"10.1016\/j.pharmthera.2022.108275_bb0825","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/0306-4522(93)90485-X","article-title":"Distribution of the messenger RNA for a metabotropic glutamate receptor, mGluR2, in the central nervous system of the rat","volume":"53","author":"Ohishi","year":"1993","journal-title":"Neuroscience"},{"issue":"2","key":"10.1016\/j.pharmthera.2022.108275_bb0830","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1002\/cne.903350209","article-title":"Distribution of the mRNA for a metabotropic glutamate receptor (mGluR3) in the rat brain: An in situ hybridization study","volume":"335","author":"Ohishi","year":"1993","journal-title":"Journal of Comparative Neurology"},{"issue":"3880","key":"10.1016\/j.pharmthera.2022.108275_bb0835","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1126\/science.164.3880.719","article-title":"Brain lesions, obesity, and other disturbances in mice treated with monosodium glutamate","volume":"164","author":"Olney","year":"1969","journal-title":"Science"},{"issue":"6","key":"10.1016\/j.pharmthera.2022.108275_bb0840","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/S0022-3956(99)00029-1","article-title":"NMDA receptor hypofunction model of schizophrenia","volume":"33","author":"Olney","year":"1999","journal-title":"Journal of Psychiatric Research"},{"issue":"3","key":"10.1016\/j.pharmthera.2022.108275_bb0845","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1021\/jm970498o","article-title":"2-Substituted (2 SR)-2-amino-2-((1 SR, 2 SR)-2-carboxycycloprop-1-yl) glycines as potent and selective antagonists of group II metabotropic glutamate receptors. 2. Effects of aromatic substitution, pharmacological characterization, and bioavailability","volume":"41","author":"Ornstein","year":"1998","journal-title":"Journal of Medicinal Chemistry"},{"issue":"3","key":"10.1016\/j.pharmthera.2022.108275_bb0850","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1021\/jm970497w","article-title":"2-Substituted (2 SR)-2-amino-2-((1 SR, 2 SR)-2-carboxycycloprop-1-yl) glycines as potent and selective antagonists of group II metabotropic glutamate receptors. 1. Effects of alkyl, arylalkyl, and diarylalkyl substitution","volume":"41","author":"Ornstein","year":"1998","journal-title":"Journal of Medicinal Chemistry"},{"issue":"9","key":"10.1016\/j.pharmthera.2022.108275_bb0855","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1038\/nm1632","article-title":"Activation of mGlu2\/3 receptors as a new approach to treat schizophrenia: A randomized Phase 2 clinical trial","volume":"13","author":"Patil","year":"2007","journal-title":"Nature Medicine"},{"issue":"11","key":"10.1016\/j.pharmthera.2022.108275_bb0860","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1021\/jm960059+","volume":"39","author":"Pellicciari","year":"1996","journal-title":"Journal of Medicinal Chemistry"},{"issue":"2","key":"10.1016\/j.pharmthera.2022.108275_bb0865","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s00213-006-0372-9","article-title":"The group II metabotropic glutamate receptor agonist, LY379268, inhibits both cocaine-and food-seeking behavior in rats","volume":"186","author":"Peters","year":"2006","journal-title":"Psychopharmacology"},{"issue":"4","key":"10.1016\/j.pharmthera.2022.108275_bb0870","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/0306-4522(95)00533-1","article-title":"The metabotropic glutamate receptors, mGluR2 and mGluR3, show unique postsynaptic, presynaptic and glial localizations","volume":"71","author":"Petralia","year":"1996","journal-title":"Neuroscience"},{"issue":"4","key":"10.1016\/j.pharmthera.2022.108275_bb0875","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1523\/JNEUROSCI.16-04-01550.1996","article-title":"Repeated cocaine augments excitatory amino acid transmission in the nucleus accumbens only in rats having developed behavioral sensitization","volume":"16","author":"Pierce","year":"1996","journal-title":"Journal of Neuroscience"},{"issue":"1\u20133","key":"10.1016\/j.pharmthera.2022.108275_bb0880","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S0014-2999(99)00258-7","article-title":"New perspectives for the development of selective metabotropic glutamate receptor ligands","volume":"375","author":"Pin","year":"1999","journal-title":"European Journal of Pharmacology"},{"issue":"3","key":"10.1016\/j.pharmthera.2022.108275_bb0885","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/S0163-7258(03)00038-X","article-title":"Evolution, structure, and activation mechanism of family 3\/C G-protein-coupled receptors","volume":"98","author":"Pin","year":"2003","journal-title":"Pharmacology & Therapeutics"},{"issue":"6","key":"10.1016\/j.pharmthera.2022.108275_bb0890","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1016\/j.bmcl.2005.01.077","article-title":"Allosteric potentiators of the metabotropic glutamate receptor 2 (mGlu2). Part 3: Identification and biological activity of indanone containing mGlu2 receptor potentiators","volume":"15","author":"Pinkerton","year":"2005","journal-title":"Bioorganic & Medicinal Chemistry Letters"},{"key":"10.1016\/j.pharmthera.2022.108275_bb0895","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.neuropharm.2014.05.008","article-title":"The metabotropic glutamate 2\/3 receptor agonist LY379268 counteracted ketamine-and apomorphine-induced performance deficits in the object recognition task, but not object location task, in rats","volume":"85","author":"Pitsikas","year":"2014","journal-title":"Neuropharmacology"},{"issue":"1","key":"10.1016\/j.pharmthera.2022.108275_bb0900","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1080\/14728214.2022.2059464","article-title":"Epilepsy: Expert opinion on emerging drugs in phase 2\/3 clinical trials","volume":"27","author":"Pong","year":"2022","journal-title":"Expert Opinion on Emerging Drugs"},{"issue":"8","key":"10.1016\/j.pharmthera.2022.108275_bb0905","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1080\/13543776.2021.1903431","article-title":"Negative allosteric modulators of group II metabotropic glutamate receptors: A patent review (2015\u2013present)","volume":"31","author":"Qunies","year":"2021","journal-title":"Expert Opinion on Therapeutic Patents"},{"issue":"2","key":"10.1016\/j.pharmthera.2022.108275_bb0910","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/(SICI)1098-2396(200002)35:2<129::AID-SYN5>3.0.CO;2-D","article-title":"Nicotine stimulation of extracellular glutamate levels in the nucleus accumbens: Neuropharmacological characterization","volume":"35","author":"Reid","year":"2000","journal-title":"Synapse"},{"issue":"2","key":"10.1016\/j.pharmthera.2022.108275_bb0915","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1002\/(SICI)1098-2396(199710)27:2<95::AID-SYN1>3.0.CO;2-6","article-title":"Cocaine and amphetamine preferentially stimulate glutamate release in the limbic system: Studies on the involvement of dopamine","volume":"27","author":"Reid","year":"1997","journal-title":"Synapse"},{"issue":"1","key":"10.1016\/j.pharmthera.2022.108275_bb0920","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.nbd.2012.03.025","article-title":"The group 2 metabotropic glutamate receptor agonist LY379268 rescues neuronal, neurochemical and motor abnormalities in R6\/2 Huntington\u2019s disease mice","volume":"47","author":"Reiner","year":"2012","journal-title":"Neurobiology of Disease"},{"key":"10.1016\/j.pharmthera.2022.108275_bb0925","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.brainres.2012.07.026","article-title":"BDNF may play a differential role in the protective effect of the mGluR2\/3 agonist LY379268 on striatal projection neurons in R6\/2 Huntington\u2019s disease mice","volume":"1473","author":"Reiner","year":"2012","journal-title":"Brain Research"},{"issue":"8","key":"10.1016\/j.pharmthera.2022.108275_bb0930","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1093\/hmg\/ddt598","article-title":"Metabotropic glutamate receptor 5 knockout promotes motor and biochemical alterations in a mouse model of Huntington\u2019s disease","volume":"23","author":"Ribeiro","year":"2014","journal-title":"Human Molecular Genetics"},{"issue":"11","key":"10.1016\/j.pharmthera.2022.108275_bb0935","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1517\/14728222.2014.948419","article-title":"Metabotropic glutamate receptor 5 as a potential therapeutic target in Huntington\u2019s disease","volume":"18","author":"Ribeiro","year":"2014","journal-title":"Expert Opinion on Therapeutic Targets"},{"issue":"5","key":"10.1016\/j.pharmthera.2022.108275_bb0940","doi-asserted-by":"crossref","first-page":"574","DOI":"10.2174\/187152710793361612","article-title":"Group I metabotropic glutamate receptor signalling and its implication in neurological disease","volume":"9","author":"Ribeiro","year":"2010","journal-title":"CNS & Neurological Disorders Drug Targets"},{"issue":"1","key":"10.1016\/j.pharmthera.2022.108275_bb0945","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12035-010-8153-1","article-title":"Huntington\u2019s disease and Group I metabotropic glutamate receptors","volume":"43","author":"Ribeiro","year":"2011","journal-title":"Molecular Neurobiology"},{"key":"10.1016\/j.pharmthera.2022.108275_bb0950","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.phrs.2016.11.013","article-title":"Metabotropic glutamate receptors and neurodegenerative diseases","volume":"115","author":"Ribeiro","year":"2017","journal-title":"Pharmacological Research"},{"issue":"1","key":"10.1016\/j.pharmthera.2022.108275_bb0955","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1750-1172-5-40","article-title":"Huntington\u2019s disease: A clinical review","volume":"5","author":"Roos","year":"2010","journal-title":"Orphanet Journal of Rare Diseases"},{"issue":"1","key":"10.1016\/j.pharmthera.2022.108275_bb0960","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.neuron.2006.09.015","article-title":"Neurobiology of schizophrenia","volume":"52","author":"Ross","year":"2006","journal-title":"Neuron"},{"issue":"22","key":"10.1016\/j.pharmthera.2022.108275_bb0965","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1056\/NEJM199205283262204","article-title":"Decreased glutamate transport by the brain and spinal cord in amyotrophic lateral sclerosis","volume":"326","author":"Rothstein","year":"1992","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1016\/j.pharmthera.2022.108275_bb0970","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/ana.410380114","article-title":"Selective loss of glial glutamate transporter GLT-1 in amyotrophic lateral sclerosis","volume":"38","author":"Rothstein","year":"1995","journal-title":"Annals of Neurology: Official Journal of the American Neurological Association and the Child Neurology Society"},{"issue":"1","key":"10.1016\/j.pharmthera.2022.108275_bb0975","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1124\/jpet.108.138271","article-title":"Transposition of three amino acids transforms the human metabotropic glutamate receptor (mGluR)-3-positive allosteric modulation site to mGluR2, and additional characterization of the mGluR2-positive allosteric modulation site","volume":"326","author":"Rowe","year":"2008","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"issue":"4","key":"10.1016\/j.pharmthera.2022.108275_bb0980","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1038\/sj.bjp.0701670","article-title":"Potentiation by DL-\u03b1-aminopimelate of the inhibitory action of a novel mGluR agonist (L-F2CCG-I) on monosynaptic excitation in the rat spinal cord","volume":"123","author":"Saitoh","year":"1998","journal-title":"British Journal of Pharmacology"},{"issue":"8","key":"10.1016\/j.pharmthera.2022.108275_bb0985","doi-asserted-by":"crossref","first-page":"4359","DOI":"10.1016\/j.bmc.2008.02.066","article-title":"Synthesis, in vitro pharmacology, and pharmacokinetic profiles of 2-[1-amino-1-carboxy-2-(9H-xanthen-9-yl)-ethyl]-1-fluorocyclopropanecarboxylic acid and its 6-heptyl ester, a potent mGluR2 antagonist","volume":"16","author":"Sakagami","year":"2008","journal-title":"Bioorganic & Medicinal Chemistry"},{"issue":"4","key":"10.1016\/j.pharmthera.2022.108275_bb0990","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1177\/0269881115573403","article-title":"Pharmacokinetic and pharmacodynamic characterisation of JNJ-40411813, a positive allosteric modulator of mGluR2, in two randomised, double-blind phase-I studies","volume":"29","author":"Salih","year":"2015","journal-title":"Journal of Psychopharmacology"},{"issue":"4","key":"10.1016\/j.pharmthera.2022.108275_bb0995","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1124\/mol.64.4.798","article-title":"Pharmacological characterization and identification of amino acids involved in the positive modulation of metabotropic glutamate receptor subtype 2","volume":"64","author":"Schaffhauser","year":"2003","journal-title":"Molecular Pharmacology"},{"issue":"1\u20132","key":"10.1016\/j.pharmthera.2022.108275_bb1000","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.brainres.2004.06.005","article-title":"The metabotropic glutamate receptor 5 antagonist MPEP and the mGluR2 agonist LY379268 modify disease progression in a transgenic mouse model of Huntington\u2019s disease","volume":"1019","author":"Schiefer","year":"2004","journal-title":"Brain Research"},{"issue":"2","key":"10.1016\/j.pharmthera.2022.108275_bb1005","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.nbd.2006.10.005","article-title":"GDNF applied to the MPTP-lesioned nigrostriatal system requires TGF-\u03b2 for its neuroprotective action","volume":"25","author":"Schober","year":"2007","journal-title":"Neurobiology of Disease"},{"issue":"1","key":"10.1016\/j.pharmthera.2022.108275_bb1010","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/S0022-3565(24)29296-X","article-title":"Unveiling the functions of presynaptic metabotropic glutamate receptors in the central nervous system","volume":"299","author":"Schoepp","year":"2001","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"issue":"10","key":"10.1016\/j.pharmthera.2022.108275_bb1015","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1016\/S0028-3908(99)00092-1","article-title":"Pharmacological agents acting at subtypes of metabotropic glutamate receptors","volume":"38","author":"Schoepp","year":"1999","journal-title":"Neuropharmacology"},{"issue":"3","key":"10.1016\/j.pharmthera.2022.108275_bb1020","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1111\/j.1471-4159.1992.tb09381.x","article-title":"Inhibition of cyclic AMP formation by a selective metabotropic glutamate receptor agonist","volume":"58","author":"Schoepp","year":"1992","journal-title":"Journal of Neurochemistry"},{"issue":"8","key":"10.1016\/j.pharmthera.2022.108275_bb1025","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/0028-3908(95)00061-A","article-title":"Selective inhibition of forskolin-stimulated cyclic AMP formation in rat hippocampus by a novel mGluR agonist, 2R, 4R-4-aminopyrrolidine-2, 4-dicarboxylate","volume":"34","author":"Schoepp","year":"1995","journal-title":"Neuropharmacology"},{"issue":"1","key":"10.1016\/j.pharmthera.2022.108275_bb1030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0028-3908(96)00160-8","article-title":"LY354740 is a potent and highly selective group II metabotropic glutamate receptor agonist in cells expressing human glutamate receptors","volume":"36","author":"Schoepp","year":"1997","journal-title":"Neuropharmacology"},{"issue":"12","key":"10.1016\/j.pharmthera.2022.108275_bb1035","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1016\/S0028-3908(96)00121-9","article-title":"The novel metabotropic glutamate receptor agonist 2R, 4R-APDC potentiates stimulation of phosphoinositide hydrolysis in the rat hippocampus by 3, 5-dihydroxyphenylglycine: Evidence for a synergistic interaction between group 1 and group 2 receptors","volume":"35","author":"Schoepp","year":"1996","journal-title":"Neuropharmacology"},{"issue":"3","key":"10.1016\/j.pharmthera.2022.108275_bb1040","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1080\/1025389031000146773","article-title":"LY354740, an mGlu2\/3 receptor agonist as a novel approach to treat anxiety\/stress","volume":"6","author":"Schoepp","year":"2003","journal-title":"Stress"},{"issue":"4","key":"10.1016\/j.pharmthera.2022.108275_bb1045","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1085\/jgp.109.4.477","article-title":"Positive and negative coupling of the metabotropic glutamate receptors to a G protein\u2013activated K+ channel, GIRK, in Xenopus oocytes","volume":"109","author":"Sharon","year":"1997","journal-title":"The Journal of General Physiology"},{"issue":"12","key":"10.1016\/j.pharmthera.2022.108275_bb1050","doi-asserted-by":"crossref","first-page":"3921","DOI":"10.1016\/j.bmcl.2012.04.112","article-title":"Development of a novel, CNS-penetrant, metabotropic glutamate receptor 3 (mGlu3) NAM probe (ML289) derived from a closely related mGlu5 PAM","volume":"22","author":"Sheffler","year":"2012","journal-title":"Bioorganic & Medicinal Chemistry Letters"},{"issue":"19","key":"10.1016\/j.pharmthera.2022.108275_bb1055","doi-asserted-by":"crossref","first-page":"7503","DOI":"10.1523\/JNEUROSCI.17-19-07503.1997","article-title":"Differential presynaptic localization of metabotropic glutamate receptor subtypes in the rat hippocampus","volume":"17","author":"Shigemoto","year":"1997","journal-title":"Journal of Neuroscience"},{"issue":"6","key":"10.1016\/j.pharmthera.2022.108275_bb1060","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1083\/jcb.200508072","article-title":"Expression of mutant huntingtin in glial cells contributes to neuronal excitotoxicity","volume":"171","author":"Shin","year":"2005","journal-title":"The Journal of Cell Biology"},{"key":"10.1016\/j.pharmthera.2022.108275_bb1065","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2020.172957","article-title":"Selective metabotropic glutamate receptor 2 positive allosteric modulation alleviates L-DOPA-induced psychosis-like behaviours and dyskinesia in the MPTP-lesioned marmoset","volume":"873","author":"Sid-Otmane","year":"2020","journal-title":"European Journal of Pharmacology"},{"issue":"2","key":"10.1016\/j.pharmthera.2022.108275_bb1070","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/S0091-3057(02)00849-3","article-title":"Group II mGluR receptor agonists are effective in persistent and neuropathic pain models in rats","volume":"73","author":"Simmons","year":"2002","journal-title":"Pharmacology Biochemistry and Behavior"},{"issue":"2","key":"10.1016\/j.pharmthera.2022.108275_bb1075","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/0006-8993(95)00383-2","article-title":"Cocaine increases extraneuronal levels of aspartate and glutamate in the nucleus accumbens","volume":"683","author":"Smith","year":"1995","journal-title":"Brain Research"},{"key":"10.1016\/j.pharmthera.2022.108275_bb1080","article-title":"Metabotropic glutamate receptors in glial cells: A new potential target for neuroprotection?","volume":"414","author":"Spampinato","year":"2018","journal-title":"Frontiers in Molecular Neuroscience"},{"issue":"1","key":"10.1016\/j.pharmthera.2022.108275_bb1085","doi-asserted-by":"crossref","first-page":"R1","DOI":"10.1016\/S0014-2999(00)00269-7","article-title":"Lack of effect of LY314582 (a group 2 metabotropic glutamate receptor agonist) on phencyclidine-induced locomotor activity in metabotropic glutamate receptor 2 knockout mice","volume":"397","author":"Spooren","year":"2000","journal-title":"European Journal of Pharmacology"},{"issue":"5","key":"10.1016\/j.pharmthera.2022.108275_bb1090","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1177\/10738584211021018","article-title":"Group 1 metabotropic glutamate receptors in neurological and psychiatric diseases: Mechanisms and prospective","volume":"28","author":"Su","year":"2021","journal-title":"The Neuroscientist"},{"issue":"1","key":"10.1016\/j.pharmthera.2022.108275_bb1095","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/0896-6273(92)90118-W","article-title":"A family of metabotropic glutamate receptors","volume":"8","author":"Tanabe","year":"1992","journal-title":"Neuron"},{"issue":"5","key":"10.1016\/j.pharmthera.2022.108275_bb1100","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1046\/j.1471-4159.2002.01062.x","article-title":"Activation of group II metabotropic glutamate receptors underlies microglial reactivity and neurotoxicity following stimulation with chromogranin A, a peptide up-regulated in Alzheimer\u2019s disease","volume":"82","author":"Taylor","year":"2002","journal-title":"Journal of Neurochemistry"},{"issue":"1","key":"10.1016\/j.pharmthera.2022.108275_bb1105","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/(SICI)1096-9861(19980105)390:1<5::AID-CNE2>3.0.CO;2-6","article-title":"Immunohistochemical localization of metabotropic glutamate receptors mGluR1a and mGluR2\/3 in the rat basal ganglia","volume":"390","author":"Testa","year":"1998","journal-title":"Journal of Comparative Neurology"},{"issue":"1","key":"10.1016\/j.pharmthera.2022.108275_bb1110","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/0922-4106(94)90227-5","article-title":"Actions of phenylglycine analogs at subtypes of the metabotropic glutamate receptor family","volume":"267","author":"Thomsen","year":"1994","journal-title":"European Journal of Pharmacology: Molecular Pharmacology"},{"issue":"1","key":"10.1016\/j.pharmthera.2022.108275_bb1115","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/S0026-895X(25)09157-6","article-title":"(2S, 1\u2019S, 2\u2019S, 3\u2019R)-2-(2\u2019-carboxy-3\u2019-phenylcyclopropyl) glycine, a potent and selective antagonist of type 2 metabotropic glutamate receptors","volume":"50","author":"Thomsen","year":"1996","journal-title":"Molecular Pharmacology"},{"issue":"7","key":"10.1016\/j.pharmthera.2022.108275_bb1120","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1080\/13543776.2019.1637421","article-title":"mGluR2 positive allosteric modulators: An updated patent review (2013\u20132018)","volume":"29","author":"Trabanco","year":"2019","journal-title":"Expert Opinion on Therapeutic Patents"},{"issue":"5","key":"10.1016\/j.pharmthera.2022.108275_bb1125","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1517\/13543776.2013.777043","article-title":"mGluR2 positive allosteric modulators: A patent review (2009 \u2013 present)","volume":"23","author":"Trabanco","year":"2013","journal-title":"Expert Opinion on Therapeutic Patents"},{"issue":"1","key":"10.1016\/j.pharmthera.2022.108275_bb1130","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/srep00926","article-title":"Group II metabotropic glutamate receptors modify N-methyl-D-aspartate receptors via Src kinase","volume":"3","author":"Trepanier","year":"2013","journal-title":"Scientific Reports"},{"issue":"1","key":"10.1016\/j.pharmthera.2022.108275_bb1135","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.bmcl.2009.11.008","article-title":"Scaffold hopping from pyridones to imidazo [1, 2-a] pyridines. New positive allosteric modulators of metabotropic glutamate 2 receptor","volume":"20","author":"Tresadern","year":"2010","journal-title":"Bioorganic & Medicinal Chemistry Letters"},{"issue":"5","key":"10.1016\/j.pharmthera.2022.108275_bb1140","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/S0960-894X(97)00068-1","article-title":"Synthesis, molecular modeling, and biology of the 1-benzyl derivative of APDC-an apparent mGluR6 selective ligand","volume":"7","author":"T\u00fcckmantel","year":"1997","journal-title":"Bioorganic & Medicinal Chemistry Letters"},{"issue":"3","key":"10.1016\/j.pharmthera.2022.108275_bb1145","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1113\/jphysiol.2003.056812","article-title":"Group II metabotropic glutamate receptors enhance NMDA receptor currents via a protein kinase C-dependent mechanism in pyramidal neurones of rat prefrontal cortex","volume":"554","author":"Tyszkiewicz","year":"2004","journal-title":"The Journal of Physiology"},{"issue":"4","key":"10.1016\/j.pharmthera.2022.108275_bb1150","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.18m12470","article-title":"Randomized, double-blind, placebo-controlled trial of the mGlu2\/3 negative allosteric modulator decoglurant in partially refractory major depressive disorder","volume":"81","author":"Umbricht","year":"2020","journal-title":"The Journal of Clinical Psychiatry"},{"issue":"1\u20132","key":"10.1016\/j.pharmthera.2022.108275_bb1155","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/S0006-8993(97)00079-6","article-title":"DCG-IV, a potent metabotropic glutamate receptor agonist, as an NMDA receptor agonist in the rat cortical slice","volume":"752","author":"Uyama","year":"1997","journal-title":"Brain Research"},{"issue":"4","key":"10.1016\/j.pharmthera.2022.108275_bb1160","article-title":"Group II metabotropic glutamate receptor agonist LY379268 regulates AMPA receptor trafficking in prefrontal cortical neurons","volume":"8","author":"Wang","year":"2013","journal-title":"PLoS One"},{"issue":"12","key":"10.1016\/j.pharmthera.2022.108275_bb1165","doi-asserted-by":"crossref","first-page":"5208","DOI":"10.1021\/jm400439t","article-title":"Discovery of (R)-(2-fluoro-4-((-4-methoxyphenyl) ethynyl) phenyl)(3-hydroxypiperidin-1-yl) methanone (ML337), an mGlu3 selective and CNS penetrant negative allosteric modulator (NAM)","volume":"56","author":"Wenthur","year":"2013","journal-title":"Journal of Medicinal Chemistry"},{"issue":"4","key":"10.1016\/j.pharmthera.2022.108275_bb1170","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1021\/jm9508144","article-title":"(2 S, 4 S)-2-Amino-4-(4, 4-diphenylbut-1-yl)-pentane-1, 5-dioic Acid: A potent and selective antagonist for metabotropic glutamate receptors negatively linked to adenylate cyclase","volume":"39","author":"Wermuth","year":"1996","journal-title":"Journal of Medicinal Chemistry"},{"issue":"1","key":"10.1016\/j.pharmthera.2022.108275_bb1175","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1750-1172-4-3","article-title":"Amyotrophic lateral sclerosis","volume":"4","author":"Wijesekera","year":"2009","journal-title":"Orphanet Journal of Rare Diseases"},{"key":"10.1016\/j.pharmthera.2022.108275_bb1180","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.cophys.2017.12.003","article-title":"Ion permeation in ionotropic glutamate receptors: Still dynamic after all these years","volume":"2","author":"Wollmuth","year":"2018","journal-title":"Current Opinion in Physiology"},{"issue":"24","key":"10.1016\/j.pharmthera.2022.108275_bb1185","doi-asserted-by":"crossref","first-page":"6811","DOI":"10.1016\/j.bmcl.2007.10.026","article-title":"Synthesis and characterization of 8-ethynyl-1, 3-dihydro-benzo [b][1, 4] diazepin-2-one derivatives: New potent non-competitive metabotropic glutamate receptor 2\/3 antagonists. Part 1","volume":"17","author":"Woltering","year":"2007","journal-title":"Bioorganic & Medicinal Chemistry Letters"},{"issue":"3","key":"10.1016\/j.pharmthera.2022.108275_bb1190","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/j.bmcl.2007.12.005","article-title":"Synthesis and characterization of 8-ethynyl-1,3-dihydro-benzo[b][1,4]diazepin-2-one derivatives: Part 2. New potent non-competitive metabotropic glutamate receptor 2\/3 antagonists","volume":"18","author":"Woltering","year":"2008","journal-title":"Bioorganic & Medicinal Chemistry Letters"},{"issue":"8","key":"10.1016\/j.pharmthera.2022.108275_bb1195","doi-asserted-by":"crossref","first-page":"2725","DOI":"10.1016\/j.bmcl.2008.02.076","article-title":"Synthesis and characterization of 1,3-dihydro-benzo[b][1,4]diazepin-2-one derivatives: Part 3. New potent non-competitive metabotropic glutamate receptor 2\/3 antagonists","volume":"18","author":"Woltering","year":"2008","journal-title":"Bioorganic and Medicinal Chemistry Letters"},{"issue":"23","key":"10.1016\/j.pharmthera.2022.108275_bb1200","doi-asserted-by":"crossref","first-page":"6969","DOI":"10.1016\/j.bmcl.2010.09.125","article-title":"Synthesis and characterization of 1, 3-dihydro-benzo [b][1, 4] diazepin-2-one derivatives: Part 4. In vivo active potent and selective non-competitive metabotropic glutamate receptor 2\/3 antagonists","volume":"20","author":"Woltering","year":"2010","journal-title":"Bioorganic & Medicinal Chemistry Letters"},{"issue":"10","key":"10.1016\/j.pharmthera.2022.108275_bb1205","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/s41580-018-0049-3","article-title":"Mechanisms of signalling and biased agonism in G protein-coupled receptors","volume":"19","author":"Wootten","year":"2018","journal-title":"Nature Reviews Molecular Cell Biology"},{"issue":"1\u20132","key":"10.1016\/j.pharmthera.2022.108275_bb1210","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/S0169-328X(97)00277-5","article-title":"Group III human metabotropic glutamate receptors 4, 7 and 8: Molecular cloning, functional expression, and comparison of pharmacological properties in RGT cells","volume":"53","author":"Wu","year":"1998","journal-title":"Molecular Brain Research"},{"issue":"6","key":"10.1016\/j.pharmthera.2022.108275_bb1215","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1038\/npp.2011.12","article-title":"Group II metabotropic glutamate receptor agonist ameliorates MK801-induced dysfunction of NMDA receptors via the Akt\/GSK-3\u03b2 pathway in adult rat prefrontal cortex","volume":"36","author":"Xi","year":"2011","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"10.1016\/j.pharmthera.2022.108275_bb1220","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1124\/jpet.300.1.162","article-title":"Group II metabotropic glutamate receptors modulate extracellular glutamate in the nucleus accumbens","volume":"300","author":"Xi","year":"2002","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.pharmthera.2022.108275_bb1225","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.neuropharm.2018.05.019","article-title":"Juvenile treatment with mGluR2\/3 agonist prevents schizophrenia-like phenotypes in adult by acting through GSK3\u03b2","volume":"137","author":"Xing","year":"2018","journal-title":"Neuropharmacology"},{"issue":"4","key":"10.1016\/j.pharmthera.2022.108275_bb1230","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1007\/s00213-006-0390-7","article-title":"An mGluR2\/3 antagonist, MGS0039, exerts antidepressant and anxiolytic effects in behavioral models in rats","volume":"186","author":"Yoshimizu","year":"2006","journal-title":"Psychopharmacology"},{"issue":"6","key":"10.1016\/j.pharmthera.2022.108275_bb1235","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S0896-6273(02)00615-3","article-title":"Increased sensitivity to N-methyl-D-aspartate receptor-mediated excitotoxicity in a mouse model of Huntington\u2019s disease","volume":"33","author":"Zeron","year":"2002","journal-title":"Neuron"},{"issue":"9","key":"10.1016\/j.pharmthera.2022.108275_bb1240","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1021\/acschemneuro.7b00098","article-title":"Synthesis and preliminary studies of a novel negative allosteric modulator, 7-((2, 5-dioxopyrrolidin-1-yl) methyl)-4-(2-fluoro-4-[11C] methoxyphenyl) quinoline-2-carboxamide, for imaging of metabotropic glutamate receptor 2","volume":"8","author":"Zhang","year":"2017","journal-title":"ACS Chemical Neuroscience"},{"issue":"2","key":"10.1016\/j.pharmthera.2022.108275_bb1245","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/S0022-3565(24)36671-6","article-title":"Increased responsiveness of ventral tegmental area dopamine neurons to glutamate after repeated administration of cocaine or amphetamine is transient and selectively involves AMPA receptors","volume":"281","author":"Zhang","year":"1997","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"issue":"9","key":"10.1016\/j.pharmthera.2022.108275_bb1250","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0106867","article-title":"GDNF-transfected macrophages produce potent neuroprotective effects in Parkinson\u2019s disease mouse model","volume":"9","author":"Zhao","year":"2014","journal-title":"PLoS One"},{"issue":"42","key":"10.1016\/j.pharmthera.2022.108275_bb1255","doi-asserted-by":"crossref","first-page":"16963","DOI":"10.1073\/pnas.1309839110","article-title":"Loss of metabotropic glutamate receptor 2 escalates alcohol consumption","volume":"110","author":"Zhou","year":"2013","journal-title":"Proceedings of the National Academy of Sciences"}],"container-title":["Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725822001693?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725822001693?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T20:05:58Z","timestamp":1777493158000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725822001693"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":251,"alternative-id":["S0163725822001693"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2022.108275","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting mGluR2\/3 for treatment of neurodegenerative and neuropsychiatric diseases","name":"articletitle","label":"Article Title"},{"value":"Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmthera.2022.108275","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108275"}}